🇺🇸 FDA
Patent

US 10548987

Antibody-drug conjugates for targeting CD56-positive tumors

granted A61KA61K2039/507A61K47/68035

Quick answer

US patent 10548987 (Antibody-drug conjugates for targeting CD56-positive tumors) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Jan 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Feb 04 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
16
CPC classes
A61K, A61K2039/507, A61K47/68035, A61K47/6849, A61K47/6851